A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2405905121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Anne E Smolko und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115. Hauptthemen laut MEDLINE: Histones, Histone Acetyltransferases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leukemia and Lymphoma Society (LLS), NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Aberrant regulation of chromatin modifiers is a common occurrence across many cancer types, and a key priority is to determine how specific alterations of these proteins, often enzymes, can be targeted therapeutically. MOZ, a histone acyltransferase, is recurrently fused to coactivators CBP, p300, and TIF2 in cases of acute myeloid leukemia (AML). Using either pharmacological inhibition or targeted protein degradation in a mouse model for MOZ-TIF2-driven leukemia, we show that KAT6 (MOZ/MORF) enzymatic activity and the MOZ-TIF2 protein are necessary for indefinite proliferation in cell culture. MOZ-TIF2 directly regulates a small subset of genes encoding developmental transcription factors, augmenting their high expression. Furthermore, transcription levels in MOZ-TIF2 cells positively correlate with enrichment of histone H3 propionylation at lysine 23 (H3K23pr), a recently appreciated histone acylation associated with gene activation. Unexpectedly, we also show that MOZ-TIF2 and MLL-AF9 regulate transcription of unique gene sets, and their cellular models exhibit distinct sensitivities to multiple small-molecule inhibitors directed against AML pathways. This is despite the shared genetic pathways of wild-type MOZ and MLL. Overall, our data provide insight into how aberrant regulation of MOZ contributes to leukemogenesis. We anticipate that these experiments will inform future work identifying targeted therapies in the treatment of AML and other diseases involving MOZ-induced transcriptional dysregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115.
- Department of Genetics, Harvard Medical School, Boston, MA 02115.
- Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
- The Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02215.
ORCID-Profile: Mitzi I Kuroda
Förderung
- Leukemia and Lymphoma Society (LLS)
- NCI NIH HHS
- NIGMS NIH HHS
- HHS | NIH | NCI | Center for Cancer Research (CCR)
- Charles A. King Trust
- American Cancer Society (ACS)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
Zitieren
APA
Smolko, A. E., Sullivan, D. W., Olsen, S. N., Kang, H., Whedon, S. D., Baell, J. B., Cole, P. A., Armstrong, S. A., & Kuroda, M. I. (2024). A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2405905121
Vancouver
Smolko AE, Sullivan DW, Olsen SN, Kang H, Whedon SD, Baell JB, et al. A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2405905121
BibTeX
@article{Smolko2024,
author = {Smolko, Anne E and Sullivan, Daniel W and Olsen, Sarah Naomi and Kang, Hyuckjoon and Whedon, Samuel D and Baell, Jonathan B and Cole, Philip A and Armstrong, Scott A and Kuroda, Mitzi I},
title = {A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2405905121}
}
EUVIMED